Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
Publications
Publications
  • January 2001 (Revised July 2003)
  • Case
  • HBS Case Collection

Pharmacyclics: Financing Research & Development

By: Malcolm P. Baker, Richard S. Ruback and Aldo Sesia
  • Format:Print
  • | Pages:14
ShareBar

Abstract

Pharmacyclics (NASDAQ: PCYC), a pharmaceutical company that manufactures products that will improve existing therapeutic treatments for cancer, arteriosclerosis, and retinal disease, was considering a $60 million private placement in February 2000. The company had more cash than ever before, but projections of R&D and marketing expenses were also unprecedented. PCYC's most promising oncology drug, a radiation enhancer called Xcytrin, was in Phase III clinical trials--the rigorous final phase before FDA approval for commercialization. Analysts gave the drug a slightly better than 50% chance of success. This case focuses on stage financing and a simple decision-tree evaluation. Students have the opportunity to consider the impact of past staged financing decisions on the ownership structure of the firm and to evaluate the current stock market price in light of analyst forecasts of the cash flow and the probability of success for each drug. These two analyses help inform the private placement decision.

Keywords

Valuation; Cash Flow; Financing and Loans; Business Startups; Financial Strategy; Medical Devices and Supplies Industry; Pharmaceutical Industry; Health Industry

Citation

Baker, Malcolm P., Richard S. Ruback, and Aldo Sesia. "Pharmacyclics: Financing Research & Development." Harvard Business School Case 201-056, January 2001. (Revised July 2003.)
  • Educators
  • Purchase

About The Authors

Malcolm P. Baker

Finance
→More Publications

Richard S. Ruback

Finance
→More Publications

More from the Authors

    • August 2020
    • Journal of Financial and Quantitative Analysis

    Leverage and the Beta Anomaly

    By: Malcolm Baker, Mathias F. Hoeyer and Jeffrey Wurgler
    • 2020
    • Faculty Research

    Financing the Response to Climate Change: The Pricing and Ownership of U.S. Green Bonds

    By: Malcolm Baker, Daniel Bergstresser, George Serafeim and Jeffrey Wurgler
    • June 2020
    • Faculty Research

    RBC: Transforming Transformation (B)

    By: Ethan Bernstein, Francesca Gino and Aldo Sesia
More from the Authors
  • Leverage and the Beta Anomaly By: Malcolm Baker, Mathias F. Hoeyer and Jeffrey Wurgler
  • Financing the Response to Climate Change: The Pricing and Ownership of U.S. Green Bonds By: Malcolm Baker, Daniel Bergstresser, George Serafeim and Jeffrey Wurgler
  • RBC: Transforming Transformation (B) By: Ethan Bernstein, Francesca Gino and Aldo Sesia
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Digital Accessibility
Copyright © President & Fellows of Harvard College